Table 2. Distribution of methylated and unmethylated DUSP2 in tissues at diagnosis (N=112) according to clinicopathological characteristics of patients.
| Characteristic | Methylated (N=51), N (%) | Unmethylated (N=61), N (%) | P value |
|---|---|---|---|
| Gender | 0.23 | ||
| Male (M) | 41 (80.4) | 54 (88.5) | |
| Female (F) | 10 (19.6) | 7 (11.5) | |
| Primary site | 0.195 | ||
| Oropharynx | 8 (15.7) | 14 (23.0) | |
| Hypopharynx | 20 (39.2) | 21 (34.4) | |
| Larynx | 6 (11.8) | 15 (24.6) | |
| Oral cavity | 16 (31.4) | 10 (16.4) | |
| Nasopharynx | 1 (2.0) | 1 (1.6) | |
| Performance status | 0.98 | ||
| PS0 | 22 (43.1) | 26 (42.6) | |
| PS1 | 27 (52.9) | 33 (54.1) | |
| PS2 | 2 (3.9) | 2 (3.3) | |
| Tumour size | <0.0001 | ||
| T1/T2 | 25 (49.0) | 9 (14.8) | |
| T3/T4 | 26 (51.0) | 52 (85.2) | |
| NA | 0 | 0 | |
| Nodal status | 0.484 | ||
| N0 | 3 (5.9) | 6 (9.8) | |
| N1 | 5 (9.8) | 9 (14.8) | |
| N2/N3 | 42 (82.4) | 46 (75.4) | |
| NA | 1 (2.0) | 0 | |
| Grade | 0.513 | ||
| G1/G2 | 22 (43.1) | 33 (54.1) | |
| G3 | 27 (52.9) | 26 (42.6) | |
| NA | 2 (3.9) | 2 (3.3) | |
| Smoke | 0.267 | ||
| Heavy smokers | 45 (88.2) | 47 (77.0) | |
| Non-smokers | 2 (3.9) | 3 (4.9) | |
| NA | 4 (7.8) | 11 (18.0) | |
| Clinical response | 0.32 | ||
| Complete remission | 29 (56.9) | 29 (47.5) | |
| Non-responders | 22 (43.1) | 32 (52.5) |
DUSP2, dual-specificity-phosphatase-2; NA, not available.